To define further the clinical importance of cytogenetic analysis in acute lymphoblastic leukaemia (ALL) a prospective study was performed on 139 unselected children. Analyses were considered adequate in 104, of whom 35 were normal and 69 had clonal abnormalities. Abnormalities were categorised according to banded chromosome analysis as well as chromosome count. Karyotypes were correlated with clinical and laboratory features at diagnosis and with survival. Of the successful analyses, thirty five (34%) children had no abnormalities; this group contained an excess of T cell disease. Twenty five (24%) had a "characteristic" hyperdiploid karyotype and as a group had lower presenting white counts, a tendency to CD1O, and periodic acid schiff positivity of the blast cells and smaller spleens. None was an infant and only one was over 10 years old. Seven (7%) children with t(9; 22), t(8; 14), or t(4; 11) translocations were grouped together as "specific" translocations. Collectively they had a significantly worse prognosis than the remainder. Nine children developed central nervous system relapse, six of whom had either t(4; 11) or abnormalities of 9p or l9p.
Key: Immunophenotype: "C" common (cytoplasmic p not determined). E = early pre-B subcategory of common; P = pre-B subcategory of common; T = T-cell; B = B-cell. Events-type: b = bone marrow relapse; c = CNS relapse; bc = bone marrow and CNS relapse; t = testicular relapse; RD = resistant disease. Time from diagnosis to event is given in months.
abnormality, and in one the position was undetermined.
The seven children with "specific" translocations included the only two cases of L3 leukaemias and, as a group, they had a worse prognosis than the other banded abnormal cases (log rank x2 = 8-7, p = <0.01), or the remaining analysable cases (log rank x2 = 7-82, p = <00 1). There was no significant difference in leukaemia free survival between any other cytogenetic groups, although when the nine cases with CNS relapse were considered, certain chromosome changes were overrepresented. These were t(4; 11) (both cases), abnormalities of 9p (two of six cases, both simple deletions), and abnormalities of 19p (two of four cases). The The striking feature of the 35 children in whom no clonal abnormality was detected was the excess of children with T cell disease-1 1 of 35 (31 %), X2 = 8-4,p = < 0 01. This confirms the results of earlier work which also showed that an excess of children with normal karyotype-19 of 38 (50%), had T cell disease,4 but it has been suggested that virtually all cases of ALL have clonal abnormalities if analyses are sufficiently detailed. 4 Although 22 of our patients had a pre-B immunophenotype, no case of the supposedly associated5 t(1; 19) translocation was observed.
In one study that translocation occurred in 19 of 79 (24%) such children,4 but in another study of 131 children with all types of ALL no examples were found, though the incidence of immunologically defined pre-B disease was not given.' It may be that the incidence of t(1; 19) is not as high as has been suggested, and its association with pre-B ALL may be less clearcut than supposed.
It has been claimed that the presence of any translocation confers a sixfold greater risk of early treatment failure compared with absence of translocation,7 and that patients with the Philadelphia chromosome, t (8; 14) and t(4; 11) have a worse prognosis than those with other translocations.' Although we were able to confirm that these "specific" translocations as a group had a worse prognosis than patients from the other abnormalities group, we were unable to detect any difference in prognosis between the latter group, all of whom had structural rearrangements, and the remaining cytogenetic categories.
We defined "characteristic" hyperdiploidy to include patients with 48-50 chromosomes if banding showed only chromosomes typical of the >50 group, and to exclude near tetraploidy. Of the three patients with near tetraploidy, one had a very high presenting white cell count and a T cell phenotype. Pui et al found a 3% incidence of T cell disease in their patients with high hyperdiploidy, but the chromosomal number was not stated.8 They too found only three cases of near tetraploidy, so small numbers prevent further analysis of this rare subgroup.
Only two (2%) of our patients had a hypodiploid clone. This is a lower incidence than the 7% found by Pui et al. 9 Neither had less than 45 chromosomes or a near haploid karyotype, both of which have been described in a substantial proportion of hypodiploid patients.'" Both were mosaics with a 45 chromosome clone combined with a normal clone, and one also had a 47 chromosome clone.
Apart from ihe apparently poor prognosis of our special translocation patients, we were unable to show any survival differences between the other chromosome groups, though our numbers are necessarily relatively small. A recent study of a similar sized group also failed to show survival differences between the conventional cytogenetic groups,6 but others have suggested that high hyperdiploidy confers an advantage,4 [11] [12] [13] [14] [15] whereas hypodiploidy bodes ill.9 These discrepancies may partly be due to small numbers and incomplete follow up, though it is at least possible that the prognostic importance of cytogenetic features could be modified by improvements in treatment. 6 There did seem to be an increased risk of CNS relapse with certain karyotypes. This occurred in both of the two t(4; 11) children, two of the six with abnormalities of 9p, and two of the four with abnormalities of 19p. It has been noted that t(4; 11) carries a high risk of relapse at any site,' and it has recently been claimed that abnormalities of the short arm of chromosome 9 confer a high risk of CNS relapse, especially where material is deleted. '6 Our data would support this. Both relapses in our 9p group had a simple deletion. Abnormalities of l9p in general have not been noted to carry a particular risk of CNS relapse, though it has recently been claimed that t(1 1; 19) has a high incidence of CNS being affected at presentation and a high risk of relapse.'7 Our sole child with that translocation did not have CNS disease at presentation, but has relapsed in both marrow and CNS.
The practice of categorising chromosomal abnormalities by using simple chromosome number predates banding. With banded karyotypes these categories should be reassessed, incorporating more precise chromosome abnormality groupings to increase their clinical usefulness. Our redefined "characteristic" hyperdiploid group, when compared with the other analysable cases, showed less striking splenomegaly and a predilection towards the 2-12 year age group. These features did not reach significance if the three near tetraploidy cases were included and the hyperdiploid cases with 50 chromosomes or less were excluded in accordance with previous classifications. The trend to longer survival was also more suggestive using our modified definition.
What can be concluded from all this? Cytogenetic analysis in ALL is undeniably very labour intensive and expensive, and its clinical importance is presently limited to the detection of clonal abnormalities in the few marrows where the diagnosis of leukaemia is in doubt, and to the prediction of outcome in a very small group of children with specific abnormalities such as those of our specific translocation group. On the other hand, it could be argued that current techniques, which may improve further, have not been applied long enough to large enough numbers for the true value of cytogenetics to emerge, and that much more work is needed.
